Skip to main content

FDA Archives

Treatment approved for patients with acute graft-versus-host disease

Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

Read more


Remote visit

Apr. 26, 2018—The chair of the U.S. Federal Communications Commission, Ajit Pai, recently visited Allen County Schools in Kentucky to see a demonstration of the new school-based telemedicine program.

Read more


Ear Community at the FDA

Mar. 22, 2018—Ron Eavey, MD, Guy M. Maness Professor and chair of Otolaryngology and director of the Vanderbilt Bill Wilkerson Center, far right, testified recently at the Food and Drug Administration in Washington, D.C., along with members of Ear Community.

Read more


Medication safety in the ICU

Sep. 19, 2017—Facilitated reporting of medication-related events in the intensive care unit can provide opportunities for optimizing quality of care and patient safety.

Read more


Investigational new drug for Alzheimer’s scheduled for first study in humans

Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Read more


Robotic advances promise artificial legs that emulate healthy limbs

Nov. 7, 2013—Recent advances in robotics technology make it possible to create prosthetics that can duplicate the natural movement of human legs which promises to dramatically improve the mobility of lower-limb amputees.

Read more


Pneumonia vaccine for children to be tested in older adults

Oct. 11, 2012—Vanderbilt is taking part in a national study to test in older adults the use of a vaccine designed to protect children against a common cause of pneumonia.

Read more


Vanderbilt-led team to develop ‘microbrain’ to improve drug testing

Jul. 24, 2012—Creating a device out of human cells that simulates brain chemistry is the goal of a $6.4 million grant which is part of major new federal initiative to develop a series of “organs on a chip” designed to improve the drug development process.

Read more


Vanderbilt study finds no heart risk in ADHD medications

Nov. 2, 2011—Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005.

Read more


Recent Stories from VUMC News and Communications Publications

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

Vanderbilt Medicine

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

VUMC campus

VUMC campus

Vanderbilt University School of Medicine entrance

Vanderbilt University School of Medicine entrance

Vanderbilt University Adult Hospital with helipad

Vanderbilt University Adult Hospital with helipad

more